All In Biotech

Drug Trial Radar · NCT06342310

RE104 Safety and Efficacy Study in Postpartum Depression

A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients With Postpartum Depression (PPD)

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Jun 14, 2024

Primary completion

May 22, 2025

Study completion Jun 16, 2025

Sponsor

Lead sponsor
Reunion Neuroscience IncIndustry
Sponsor type
Industry
First posted
Apr 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.

Conditions

  • Postpartum Depression

Interventions

  • RE104 for InjectionDrug

    Single, subcutaneous dose of RE104 for Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total scoreTime frame: Day 7

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Reunion Investigational Site

    Birmingham, Alabama

  • Reunion Investigational Site

    Tucson, Arizona

  • Reunion Investigational Site

    Santa Monica, California

  • Reunion Investigational Site

    Boulder, Colorado

  • Reunion Investigational Site

    Denver, Colorado

  • Reunion Investigational Site

    Lauderhill, Florida

  • Reunion Investigational Site

    Tampa, Florida

  • Reunion Investigational Site

    Atlanta, Georgia

  • Reunion Investigational Site

    Atlanta, Georgia

  • Reunion Investigational Site

    Decatur, Georgia

  • Reunion Investigational Site

    Marietta, Georgia

  • Reunion Investigational Site

    Savannah, Georgia

  • Reunion Investigational Site

    Honolulu, Hawaii

  • Reunion Investigational Site

    Kansas City, Kansas

  • Reunion Investigational Site

    Shreveport, Louisiana

  • Reunion Investigational Site

    Baltimore, Maryland

  • Reunion Investigational Site

    Rockville, Maryland

  • Reunion Investigational Site

    Springfield, Massachusetts

  • Reunion Investigational Site

    Novi, Michigan

  • Reunion Investigational Site

    Albuquerque, New Mexico

  • Reunion Investigational Site

    Buffalo, New York

  • Reunion Investigational Site

    New York, New York

  • Reunion Investigational Site

    New York, New York

  • Reunion Investigational Site

    Chapel Hill, North Carolina

  • Reunion Investigational Site

    Monroe, North Carolina

  • Reunion Investigational Site

    Cleveland, Ohio

  • Reunion Investigational Site

    Columbus, Ohio

  • Reunion Investigational Site

    West Chester, Pennsylvania

  • Reunion Investigational Site

    Austin, Texas

  • Reunion Investigational Site

    Austin, Texas

  • Reunion Investigational Site

    Austin, Texas

  • Reunion Investigational Site

    Plano, Texas

  • Reunion Investigational Site

    San Antonio, Texas

  • Reunion Investigational Site

    Draper, Utah

  • Reunion Investigational Site

    Salt Lake City, Utah

  • Reunion Investigational Site

    Charlottesville, Virginia

  • Reunion Investigational Site

    Seattle, Washington

  • Reunion Investigational Site

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.